Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021
GBD 2021 Rheumatoid Arthritis Collaborators, Wafa Ali Aldhaleei(Mayo Clinic in Arizona), Fatemeh Afrashteh(University of Washington), Mohammad Amin Aalipour(Shahid Beheshti University of Medical Sciences), Habeeb Abiodun Afolabi, Prince Owusu Adoma(University of Education, Winneba), Temitayo Esther Adeyeoluwa(University of Ibadan), Armita Abedi, Juliana Bunmi Adetunji, Kamoru A. Adedokun(Roswell Park Comprehensive Cancer Center), Sindew Mahmud Ahmed, Meriem Abdoun, Dariush Abtahi, Dina Abushanab(Hamad Medical Corporation), Bilyaminu Abubakar(Nigerian Institute of Medical Research), Sajjad Ahmad(Moorfields Eye Hospital NHS Foundation Trust), Mostafa Alam, David Adzrago(National Institutes of Health), Negar Sadat Ahmadi, Mohamed Abouzid(Poznan University of Medical Sciences), Richard Gyan Aboagye(University of Health and Allied Sciences), Ahmad Y. Abuhelwa(University of Sharjah), Fahmi Y. Al-Ashwal(University of Science and Technology), Vlad-Adrian Afrăsânie(Institutul Regional de Oncologie), Muayyad M Ahmad, Yi Deun Jeong(Kyung Hee University), Muktar Beshir Ahmed(Jimma University), Salahdein Aburuz(University of Jordan), Olumide Thomas Adeleke(Bowen University), Mohd Adnan, Ali Ahmed, Auwal Abdullahi, Seoyoung Park, Danish Ahmad, Min Seo Kim, A Bhoomadevi, Lisa C Adams, Aqeel Ahmad, Eman Abu-Gharbieh, Syed Anees Ahmed, Yazan Al-Ajlouni, Mahsa Ahadi, Toufik Abdul-Rahman, Ayman Ahmed, Nurudeen A Adegoke, Saira Afzal, Williams Agyemang-Duah, Mohammed Abdalla(University of East Anglia), Bright Opoku Ahinkorah, Wonwoo Jang(Kyung Hee University)
Cited by 0
Related Papers
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet|2023|4.5k